Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 5, 2016, discloses events occurring on March 30, 2016. Citius Pharmaceuticals, Inc. (the "Company") completed a merger with Leonard-Meron Biosciences, Inc. ("LMB"), a late-stage specialty pharmaceutical company. The transaction was structured as a reverse merger where LMB became the surviving corporation, effectively changing the Company's primary business focus to the development of critical care anti-infectives.
Key Financial Metrics and Transaction Details
- Merger Consideration: LMB shareholders received 1.81 shares of Citius Common Stock for each share of LMB common stock. LMB shareholders now own approximately 41% of the combined company.
- Financing: Prior to closing, the Company issued 5,000,000 shares of common stock to Leonard Mazur at $0.60 per share, raising $3,000,000 in aggregate proceeds.
- Executive Compensation: Myron Holubiak was appointed CEO with a 3-year employment agreement including a $450,000 annual base salary and a discretionary bonus up to 50% of base salary.
- Financial Statements: The filing states that financial statements for the acquired business (LMB) will be provided in an amendment within 71 calendar days. No historical revenue, profit, or cash flow data for LMB is included in this specific text.
Material Changes
- Corporate Structure: The Company merged with LMB, resulting in LMB continuing as the surviving entity.
- Leadership Changes: Myron Holubiak was appointed President and CEO. Leonard Mazur was appointed Chairman and Secretary. The Board of Directors was expanded to include Suren Dutia, Carol Webb, Dr. William Kane, and Howard Safir.
- Control: A Voting Agreement was executed granting Leonard Mazur the right to appoint a majority of the Board of Directors until the Company is listed on a national securities exchange.
- Asset Acquisition: The Company acquired LMB's primary asset, Mino-LokTM, a phase 3-ready antibiotic lock solution for treating catheter-related bloodstream infections (CRBSIs).
Outlook, Risks, and Management Commentary
Product Pipeline and Market Opportunity: The Company's primary focus is now Mino-LokTM, which received Qualified Infectious Disease Product (QIDP) designation from the FDA in October 2015. This designation offers Fast Track status, Priority Review, and potential 5 years of additional market exclusivity. LMB estimates a U.S. market potential of approximately $600 million annually. The Company plans to conduct a Phase 3 study in 700 patients and believes an NDA could be approved within 2.5 years.
Risks and Contingencies:
- Regulatory Risk: Success depends on FDA approval of the Phase 3 protocol and subsequent NDA. The FDA requires two adequate and well-controlled clinical trials for approval.
- Competition: While no direct competitors for salvage therapy are currently approved, agents like Neutrolin (CorMedix) and B-Lock (Great Lakes Pharmaceuticals) are in development for prevention.
- Financial Risk: The Company relies on future financing or revenue generation to fund the Phase 3 trial and commercialization.
Investor Verification Checklist
- Verify the upcoming filing of LMB's audited financial statements (due within 71 days of this report) to assess the acquired entity's historical liquidity and debt.
- Confirm the status of the Phase 3 clinical trial protocol submission and FDA acceptance.
- Review the Voting Agreement terms regarding Leonard Mazur's control over the Board and the conditions for its termination.
- Monitor the Company's cash burn rate and capital requirements to fund the planned Phase 3 study.
- Assess the competitive landscape updates regarding CorMedix and Great Lakes Pharmaceuticals.